Evidence mapPaperPMID 41003796Full record

ReviewMetabolic brain disease2025

From metabolic dysregulation to neurodegenerative pathology: the role of hyperglycemia, oxidative stress, and blood-brain barrier breakdown in T2D-driven Alzheimer's disease.

Ahmad Raza, Shafaq Saleem, Samar Imran, Sarah Rahman, Muhammad Haroon, Azeen Razzaq, Ahmad Hussain, Javed Iqbal, Brijesh Sathian

Abstract readReview
In one paragraph

Review in Metabolic brain disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Functional PET imaging of gut microbiota with [European journal of nuclear medicine and molecular imaging · 2026
    Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ahmad RazaDepartment of Medicine, Rawalpindi Medical University, Rawalpindi, Pakistan.
Shafaq SaleemDepartment of Medicine, Rawalpindi Medical University, Rawalpindi, Pakistan.
Samar ImranDepartment of Neurology, Fauji Foundation Hospital, Rawalpindi, Pakistan.
Sarah RahmanDepartment of Medicine, Rawalpindi Medical University, Rawalpindi, Pakistan.
Muhammad HaroonDepartment of Medicine, Rawalpindi Medical University, Rawalpindi, Pakistan.
Azeen RazzaqDepartment of Medicine, Rawalpindi Medical University, Rawalpindi, Pakistan.
Ahmad HussainPunjab Medical College, Faisalabad, Pakistan.
Javed IqbalHamad Medical Corporation, P.O Box 3050, Doha, Qatar. jiqbal3@hamad.qa.ORCID 0000-0003-2627-685X
Brijesh SathianHamad Medical Corporation, P.O Box 3050, Doha, Qatar.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Type 2 Diabetes (T2D) and Alzheimer's Disease (AD) share common risk factors that can be seen through T2D nearly doubling an individual's likelihood of developing AD. Some AD patients show signs of metabolic dysfunction as well. This review focuses on the potential mechanisms associated with these two diseases, like insulin resistance, inflammation, oxidative damage, mitochondrial injury, and cell death. One of the notable elements in this connection is the "brain insulin resistance," most frequently named as "type 3 diabetes," which impairs glucose metabolism and facilitates amyloid beta (Aβ) plaque synthesis while reducing the action of insulin-degrading enzyme (IDE). Moreover, the overactivity of glycogen synthase kinase-3 beta (GSK-3β) also triggers taurine protein pathology. Raised concentrations of glucose in blood can produce advanced glycation end products (AGEs), which further exacerbate neuroinflammation in tandem with the mitigation of neurotoxic Aβ oligomers. Inflammation and subsequent damage to mitochondria lead to the dissolution of synapses. Current vascular insults include the breakdown of the blood-brain barrier (BBB) and decreased brain perfusion, along with other contributory factors to conditions conducive to neurotoxicity. Recently, novel therapies are emerging, including GLP-1 agonists, intranasal insulin, and mitochondrial antioxidants, that show surprising results for treating both conditions, but on the contrary, bioavailability and the timing of interventions remain a big challenge in the management of these diseases. Eventually, further research should center on understanding the mechanisms of integration along with the development of molecular biology, neuroimaging, and outcome-driven treatment strategies. Comprehensive strategies that exist between T2D-AD for integration and preservation of brain and metabolic health are addressed in this review.

Indexed as

Alzheimer DiseaseBlood-Brain BarrierDiabetes Mellitus, Type 2HyperglycemiaOxidative StressAnimalsBrainHumansInsulin ResistanceAdvanced glycation end products (AGEs)Alzheimer’s disease (AD)Amyloid-beta (Aβ) accumulationInsulin resistanceMitochondrial dysfunctionNeuroinflammationType 2 diabetes mellitus (T2D)

Identifiers

PMID41003796
PMCPMC12474712

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.